Q3 2026 Globus Medical, Inc. Earnings Conference Call - GLOBUS MEDICAL INC

Financial Performance:

• Q3 2026 total revenue was $763.7 million, a 0.7% decline as-reported (0.5% constant currency); Base business revenue (excluding Nevro) grew 3% to $690 million.
• Non-GAAP EPS was $1.23, up 4% year-over-year; GAAP EPS was $1.04.
• Record Free Cash Flow (FCF) reached $225 million despite a 13% increase in capital expenditures; Operating cash flow was $265 million.
• Adjusted Gross Profit Margin expanded to 69.5% (up 140 bps YoY) for the eighth consecutive quarter; Full-year 2026 adjusted gross margin guidance is 69-70%.
• Adjusted EBITDA margin was 34.3% (up 150 bps YoY), with Nevro adjusted EBITDA margins expanding 370 bps to a sustainable 19.9% run rate.
• Share repurchases totaled $142.9 million (1.9M shares) in Q3; Board authorized an additional $500 million buyback, leaving $110 million remaining under the 2025 program.
• Cash, cash equivalents, and marketable securities stood at $871.2 million at quarter-end.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance lowered to $3.09 billion (previously $3.18-$3.22B), implying ~5.1% growth over 2025; Non-GAAP EPS guidance reiterated at $4.95-$5.05.
• 2026 growth will be depressed by delayed product launches and Nevro recovery timing; meaningful revenue contribution from new products (Scrip, EIQ, XLIF prone) expected in 2027.
• Long-term growth targets for 2027 include mid-to-high single-digit top-line growth with earnings outpacing revenue growth due to operating leverage.
• Management expects R&D spending to increase as a percentage of sales in 2027 to support new product development.
• Confident in stabilizing and growing the U.S. Spine business above market rates, driven by new product momentum, sales force expansion, and robot pull-through.

Business Segments and Product Lines:

• U.S. Spine: Grew 2% YoY; growth impacted by delayed launches and lower competitive recruiting contributions; expected to accelerate in 2027.
• Enabling Technologies: Revenue grew 24% to $34.9 million; eGPS and eHub units deployed grew 73% YoY; transition to rental/lease models increased unit sales 45% YoY.
• Trauma: Grew 19% YoY; business shifting from "dabbling" to committed focus, targeting utilization in Level 1 and 2 trauma centers.
• Nevro: Revenue declined 26% to $73.7 million due to lower trial volumes; hiring and training of sales force is complete; new IPG "HFX Elite" with bolus therapy and expanded MRI labeling slated for H1 2027 launch.
• New Product Launches: "Scrip" patient-specific implants (7 new 3D-printed cages/rods) now available; "XLIF prone" solution and "two-blade retractor" launching later this quarter; "EIQ" suite (AI planning, rod bending, neural monitoring) in final stages for 2027 release.

Market and Competitive Landscape:

• Market dynamics characterized by timing delays in product introductions and intense competition in competitive recruiting; management declined to cite broad market slowdowns, attributing misses to execution and product timing.
• U.S. Spine market growth expected to be outpaced by Globus via differentiated innovations (Scrip, EIQ) and capital attachment from robotics.
• International revenue declined 5.7% as-reported (5% constant currency), driven primarily by Nevro and persistent softness in Japan; excluding Nevro, international growth remains strong at 11.6% YTD.
• Competitive recruiting strategy involves increasing the volume of new reps and ensuring successful integration of their existing revenue.

Risks and Challenges:

• Execution risks related to delayed product launches (Scrip, EIQ) reducing near-term revenue; manufacturing and production issues are being resolved but lingering.
• Nevro's recovery timeline has been delayed beyond expectations, requiring sustained sales force deployment to regain trial volumes.
• Potential headwinds in Japan and international markets due to integration disruptions and slower growth rates.
• Increased R&D spending in 2027 may partially offset gross margin improvements.
• Biologics pricing remains highly competitive and separate from implant contracts.

Management Commentary and Tone:

• Tone remains confident and focused on the "long game," acknowledging short-term bumps but emphasizing strong 2027 positioning.
• CEO Keepe Feil (also referred to as Keith in Q&A) highlighted that delays were execution-related rather than indicative of market weakness, expressing strong belief in the 2027 growth trajectory.
• CFO Kyle Klein emphasized record cash generation and the successful integration of Nevro's cost controls, despite revenue declines.
• Management reaffirmed capital allocation strategy prioritizing R&D, sales force expansion, share buybacks, and strategic tuck-in acquisitions.

Analyst Questions and Answers:

• Market Growth: CEO clarified that market softness was not a primary driver; Q3 misses were due to product launch delays (Scrip, XLIF prone) and slower-than-expected competitive rep ramp-up.
• Q4 Outlook: Guidance implies mid-single-digit Q4 decline driven by Nevro, tough comps in Enabling Tech (upfront revenue vs. recurring), and Spine launch timing.
• Delayed Product Impact: Management stated "backlog" is better described as "anticipation"; Scrip and prone solution are expected to drive 2027 growth.
• International/Japan: Softness in Japan is a structural, slower-growth market issue rather than a new disruption; excluding Nevro, international performance remains positive.
• M&A Strategy: Recent small acquisitions (Higgs Boson, Synaptive) are "tuck-ins" not revenue contributors in 2027; focused on surgical intelligence (Higgs) and cranial expansion (Synaptive).
• Trauma M&A: Not a near-term priority; focus remains on organic growth in a "full bag" business.
• Biologics: Pricing is competitive; strategy focuses on increasing attachment rates within procedures rather than price wars.

Other Key Points:

• Corporate Leadership: Shagun Singh (new SVP of Strategy and Investor Relations) joined, separating IR from Corporate Development led by Brian Kearns.
• FDA Update: FDA closed the July 2024 eGPS warning letter; no patient safety issues involved, only administrative tracking.
• Strategic Acquisitions: Acquired Synaptive assets to enter the cranial neurosurgery market (est. 2M procedures/year) and Higgs Boson for AI/surgical intelligence data layer.
• Capital Deployment: Transition to flexible capital acquisition (rentals/leases) is driving unit growth, though it impacts Q4 upfront revenue recognition.
• 2027 Catalysts: Full suite of new products (Scrip, EIQ, HFX Elite) and completed sales force hiring are the primary drivers for the 2027 turnaround.